

INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY

Effective Date: February 26, 2015

Review Dates: 2/08, 2/09, 2/10, 2/11, 2/12, 2/13, 2/14,
2/15, 2/16, 2/17, 2/18, 2/19

Date Of Origin: January 3, 2008

Status: Current

I. POLICY/CRITERIA

Intraperitoneal hyperthermic chemotherapy (IPHC) may be covered when recommended by the National Comprehensive Cancer Network (NCCN) Guidelines.

Intraperitoneal hyperthermic chemotherapy (IPHC) not recommended by NCCN may be covered as part of a clinical trial when the criteria of the Clinical Trials medical policy are met.

II. MEDICAL NECESSITY REVIEW

Required Not Required Not Applicable

III. APPLICATION TO PRODUCTS

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- ❖ **HMO/EPO:** *This policy applies to insured HMO/EPO plans.*
- ❖ **POS:** *This policy applies to insured POS plans.*
- ❖ **PPO:** *This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.*
- ❖ **ASO:** *For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.*
- ❖ **INDIVIDUAL:** *For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.*
- ❖ **MEDICARE:** *Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, this policy applies.*
- ❖ **MEDICAID/HEALTHY MICHIGAN PLAN:** *For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html, the Michigan Medicaid Provider Manual will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.*

IV. DESCRIPTION

Intraperitoneal hyperthermic chemotherapy (IPHC) is used as an adjunct to surgery for the treatment of some cancers that have penetrated or metastasized into the peritoneal cavity. The goal of IPHC is to enhance the cytotoxic effect of chemotherapeutic drugs, thereby killing disseminated tumor cells and reducing the risk of tumor recurrence.

IPHC involves using a heated sterile solution that is circulated throughout the abdominal cavity. With IPHC treatment, patients are connected to a series of tubes and a pumping device that bathe the abdominal cavity with a heated sterile solution containing anticancer (chemotherapeutic) drugs. The high temperature has been found to increase the drug's effect. The fluid goes through the abdomen to treat tumor cells that may remain after surgery. Both heat and direct contact with chemotherapy drugs kills the cancer cells.

V. CODING INFORMATION

ICD-10 Codes that may apply:

C45.1	Mesothelioma of peritoneum
C48.0 – C48.8	Malignant neoplasm of retroperitoneum and peritoneum
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum

CPT/HCPCS Codes:

96549	Unlisted chemotherapy procedure (<i>Explanatory notes must accompany claims billed with unlisted codes.</i>)
-------	--

Coding Notes: CPT code 96446 identifies chemotherapy administration into the peritoneal cavity via indwelling port or catheter. When performed using a temporary catheter or performed intraoperatively, the unlisted code 96549 should be reported. This procedure does not refer to external application of heat as described by CPT 77605. Heating of the chemotherapy agent for IPHC is not separately payable.

VI. REFERENCES

1. Aetna. Clinical Policy Bulletins. Hyperthermia in Cancer Therapy. http://www.aetna.com/cpb/medical/data/200_299/0278.html (Accessed January 9, 2019).
2. Cigna Medical Coverage Policy. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) @ https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm_0396_coveragepositioncriteria_intraperitoneal_hyperthermic_chem

- otherapy.pdf (Retrieved December 30, 2014, December 16, 2015, January 4, 2017, January 5, 2018 & January 9, 2019)
3. Hayes Directory: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers. June 10, 2006. Accessed January 4, 2008
 4. Hyperthermia in Cancer Therapy, Aetna Clinical Policy Bulletin @ http://www.aetna.com/cpb/medical/data/200_299/0278.html (Retrieved December 30, 2014, December 16, 2015, January 4, 2017, & January 9, 2019)
 5. National Comprehensive Cancer Network (NCCN). NCCN Guidelines, Colon Cancer, version 4.2018. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (Accessed January 9, 2019).
 6. Piso P, Dahlke MH, Loss M, Schlitt HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. *World J Surg Oncol*. 2004 Jun 28;2:21
 7. Roviello F, Marrelli D, Neri A, Cerretani D, de Manzoni G, Pedrazzani C, Cioppa T, Nasti G, Giorgi G, Pinto E. Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity. *World J Surg*. 2006 Nov;30(11):2033-40
 8. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, McQuellon R, Geisinger KR, Loggie BW. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. *Arch Surg*. 2003 Jan;138(1):26-33
 9. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg*. 2007 Jan; 245(1):104-9.
 10. Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, Levine EA. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. *Ann Surg Oncol*. 2004 Feb; 11(2):178-86.
 11. Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma--a prospective study of 70 consecutive cases. *Ann Surg Oncol*. 2007 Feb; 14(2):515-25.
 12. Yan TD, Sim J, Morris DL. Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. *Ann Surg Oncol*. 2007 Jun;14(6):1807-17

AMA CPT Copyright Statement:

All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Insurance Company and Priority Health Government Programs, Inc.